Coyne, Cody

C.P. Coyne, DVM., PhD., DACVIM
Professor, Molecular Pharmacology and Immunology
Department of Basic Sciences

Contact Information
College of Veterinary Medicine
P.O. Box 6100
Mississippi State, MS 39762-6100
Phone: 662-325-1120
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


  • D.V.M. – Colorado State University
  • Internship – University of California-Davis
  • Ph.D. – University of California at Davis
  • Residency – University of California at Davis
  • Diplomate – American College of Veterinary Internal Medicine
  • Research – Application of molecular biology and proteomics analyses to delineate mechanisms of disease associated with immunological processes and neoplastic conditions as an investigational basis for the molecular design of pharmaceutical and biopharmaceutical agents. Investigations have also been devoted to the development of novel vaccine preparations.

  • Teaching – Graduate Research Students: pharmaceutical molecular design, molecular oncology, proteomics, modification of gene transcription, molecular pathogenesis of septic and non-septic inflammatory reactions Veterinary Students: pharmacology and internal medicine

  • Research - Molecular Pharmacology

  • Discovery of molecular mechanisms of disease (biochemical / genetic) "targets" that can be applied as templates for the design of pharmaceutical and biopharmaceutical agents.
  • Anti-neoplatic properties of electromagnetic fields
  • Strategies for modifying the molecular pathogenesis of intense septic and non-septic inflammatory responses
  • Strategies for modifying the molecular pathogenesis of hyper-immune and auto-immune disease states
  • Mononuclear cell (macrophage/lymphocyte) and neoplastic cell proteomics
  • Diagnotic pharmacology in investigative research and clinical medicine

Parasite vaccine development

Publication of Research Manuscripts and Contributions to the Medical Literature

Coyne CP (MSU), Jones T, Bear R. Synthesis of gemcitabine-(C4-amide)-[anti-HER2/neu] utilizing a UV-photoactivated gemcitabine intermediate: cytotoxic anti-Neoplastic activity against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3. Accepted August 14, 2012 Journal of Cancer Therapy: Breast Cancer Special Issue.